Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma

Ruxolitinib inhibits poly(I:C) and type 2 cytokines‐induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma

Abstract Rationale Severe eosinophilic asthma is characterized by airway eosinophilia and corticosteroid‐resistance, commonly overlapping with type 2 inflammation. It has been reported that chemokine (C‐C motif) ligand 5 (CCL5) is involved in the exacerbation of asthma by RNA virus infections. Indee...

Full description

Bibliographic Details
Main Authors: Mitsuru Sada, Masato Watanabe, Toshiya Inui, Keitaro Nakamoto, Aya Hirata, Masuo Nakamura, Kojiro Honda, Takeshi Saraya, Daisuke Kurai, Hirokazu Kimura, Haruyuki Ishii, Hajime Takizawa
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Immunity, Inflammation and Disease
Subjects:
CCL5
eosinophilic asthma
ruxolitinib
bronchial epithelium
IL‐13
Online Access:https://doi.org/10.1002/iid3.397

Internet

https://doi.org/10.1002/iid3.397

Similar Items